Claim Unresolvable
REGENXBIO expects to complete enrollment of approximately 30 patients a...
REGENXBIO: REGENXBIO expects to complete enrollment of approximately 30 patients aged 1+ in the U.S.... Published Aug 7, 2025. Status: Unresolvable. The claim...
REGENXBIO expects to complete enrollment of approximately 30 patients aged 1+ in the U.S. and Canada for the AFFINITY DUCHENNE® pivotal trial of RGX-202 for Duchenne muscular dystrophy.
FactTracker assessment
The claim states an expectation for REGENXBIO to complete patient enrollment by a deadline of October 31, 202...
Original source: ir.regenxbio.com